Letters
Cost-effectiveness analysis should be mandatory in clinical-effectiveness research
Bharath Kumar Tirupakuzhi Vijayaraghavan, Xavier Willaert and Brian H. Cuthbertson
CMAJ October 15, 2019 191 (41) E1140; DOI: https://doi.org/10.1503/cmaj.73298
Bharath Kumar Tirupakuzhi Vijayaraghavan
Consultant, Department of Critical Care Medicine, Apollo Hospitals; Chennai Critical Care Consultants Group, Chennai, India
MDXavier Willaert
Consultant, Department of Critical Care Medicine, ZOL, Genk, Belgium
MDBrian H. Cuthbertson
Professor of Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.
MDIn this issue
Article tools
Cost-effectiveness analysis should be mandatory in clinical-effectiveness research
Bharath Kumar Tirupakuzhi Vijayaraghavan, Xavier Willaert, Brian H. Cuthbertson
CMAJ Oct 2019, 191 (41) E1140; DOI: 10.1503/cmaj.73298
Related Articles
Cited By...
- Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial
- Economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): study protocol